Bausch Health acquires Eton Pharmaceuticals' EM-100 investigational eye drops
Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, will be the first OTC preservative-free formulation eye drop for treatment of ocular itching associated with allergic conjunctivitis. February 19, 2019